PELP1 and prostate carcinoma: A recent study suggests that PELP1 mediates androgen receptor activation in the absence of androgens in PCa cells and that disruption of the complex between androgen receptor and PELP1 may be a viable therapeutic strategy in advanced prostate cancer [34].